The nonclassic secretion of thioredoxin is not sensitive to redox stateTANUDJI, Marcel; HEVI, Sarah; CHUCK, Steven L et al.American journal of physiology. Cell physiology. 2003, Vol 53, Num 5, pp C1272-C1279, issn 0363-6143Article

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week ResultsELION, Richard; MOLINA, Jean-Michel; CHUCK, Steven L et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 4, pp 494-497, issn 1525-4135, 4 p.Article

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical TrialZOLOPA, Andrew R; BERGER, Daniel S; LAMPIRIS, Harry et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 814-822, issn 0022-1899, 9 p.Article